Sandoz wins Generics Bulletin ‘Biosimilars Initiative of the Year’ award

Holzkirchen, October 13, 2014 – Sandoz is pleased to announce that Generics Bulletin, a newsletter covering commercial and regulatory information for the global generics industry, has awarded the company with “Biosimilars Initiative of the Year”, for its file acceptance of G-CSF (filgrastim) in the US. Sandoz also achieved top-three podium positions in the Company of the Year; Company of the Year – Americas; and Innovation of the Year Awards categories.

On July 24, Sandoz, announced that the FDA accepted its application for filgrastim, making Sandoz the first company …

/by

Sandoz wins Generics Bulletin ‘Biosimilars Initiative of the Year’ award

Holzkirchen, October 13, 2014 – Sandoz is pleased to announce that Generics Bulletin, a newsletter covering commercial and regulatory information for the global generics industry, has awarded the company with “Biosimilars Initiative of the Year”, for its file acceptance of G-CSF (filgrastim) in the US. Sandoz also achieved top-three podium positions in the Company of the Year; Company of the Year – Americas; and Innovation of the Year Awards categories.

On July 24, Sandoz, announced that the FDA accepted its application for filgrastim, making Sandoz the first company …

/by

Sandoz commits to providing affordable, quality eye care on World Sight Day

October 9, 2014 – Approximately 285 million people worldwide live with low vision and blindness, according to the World Health Organization. Of these, 39 million people are blind and 246 million have moderate or severe visual impairment. Often a result of poor living conditions, 90% of blind people live in low-income countries.

…
/by

Sandoz commits to providing affordable, quality eye care on World Sight Day

October 9, 2014 – Approximately 285 million people worldwide live with low vision and blindness, according to the World Health Organization. Of these, 39 million people are blind and 246 million have moderate or severe visual impairment. Often a result of poor living conditions, 90% of blind people live in low-income countries.

…
/by

Sandoz receives approval in Portugal for innovative respiratory inhaler AirFluSal® Forspiro®

  • Portuguese Health Authority grants marketing authorization for AirFluSal® Forspiro®
  • Approval for 50-250 and 50-500µg dosage forms
  • AirFluSal Forspiro already launched in four European countries and South Korea

Holzkirchen, October 09, 2014 – Sandoz announces today that the Portuguese Health Authority (Infarmed) has granted marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

AirFluSal Forspiro has now been approved in a total of 10 …

/by

Sandoz receives approval in Portugal for innovative respiratory inhaler AirFluSal® Forspiro®

  • Portuguese Health Authority grants marketing authorization for AirFluSal® Forspiro®
  • Approval for 50-250 and 50-500µg dosage forms
  • AirFluSal Forspiro already launched in four European countries and South Korea

Holzkirchen, October 09, 2014 – Sandoz announces today that the Portuguese Health Authority (Infarmed) has granted marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

AirFluSal Forspiro has now been approved in a total of 10 …

/by

US celebrates 30 years of rapid generics growth

October 01, 2014 – 30 years ago, when President Ronald Reagan signed the legislation that would lay the basis for today’s US generics industry, even the law’s biggest fans never guessed quite how successful it would be.

One estimate – optimistic at the time – was that the new legislation, commonly known today as the Hatch Waxman Act, could save Americans a total of USD 1 billion.

A study published this year by the IMS Institute for …

/by

US celebrates 30 years of rapid generics growth

October 01, 2014 – 30 years ago, when President Ronald Reagan signed the legislation that would lay the basis for today’s US generics industry, even the law’s biggest fans never guessed quite how successful it would be.

One estimate – optimistic at the time – was that the new legislation, commonly known today as the Hatch Waxman Act, could save Americans a total of USD 1 billion.

A study published this year by the IMS Institute for …

/by

Sandoz contributes to fighting the number one cause of death globally

September 29, 2014 – Today is World Heart Day. Cardiovascular disease (CVD) is a global burden accounting for 17.3 million deaths a year – significantly more than all deaths related to malaria, HIV and tuberculosis. By 2030, the World Health Organization estimates more than 23 million people annually will die of CVD.

Due to the prevalence of CVD globally, affordable medicines are a top concern for governments and health authorities. Sandoz has a broad portfolio of generic cardiovascular medications which prevent cardiovascular diseases by lowering lipid levels and …

/by

Sandoz continues women leadership program to build talent pipeline

Holzkirchen, Germany, September 26, 2014 – For the fourth consecutive year, Sandoz held the global Women@Sandoz leadership program for top women associates. Eighteen women, representing all Sandoz regions and functions, participated in the three-day event, sponsored by Sandoz Global Head, Richard Francis.

 

“We are focused on achieving and maintaining a strong gender balance at all levels, in every area of our business, because we believe diversity is good for business and inclusion is good for our people,” said Lisa Richert, Sandoz Chair of the Global …

/by